MD Anderson Cancer Cente

Houston, Texas 77030

0 studies enrolling now · 1 studies all time

What they study most

Myelodysplastic Neoplasm, Myeloproliferative Neoplasm, Pathway Mutant Myelodysplastic Syndromes

Studies at this site

• Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms — Withdrawn before enrolling